<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mast cells (MC) are multipotent hemopoietic effector cells producing diverse mediators like <z:chebi fb="11" ids="18295">histamine</z:chebi>, <z:chebi fb="5" ids="28304">heparin</z:chebi>, or tissue type plasminogen activator </plain></SENT>
<SENT sid="1" pm="."><plain>We report a 75-year-old male patient with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) of recent <z:hpo ids='HP_0003674'>onset</z:hpo> (3 months' history) associated with a massive leukemic spread of immature tryptase+ MC (tentative term: myelomastocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>The patient presented with <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, <z:mp ids='MP_0001914'>bleeding</z:mp>, <z:hpo ids='HP_0011900'>hypofibrinogenemia</z:hpo>, and an increased cellular tryptase level </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, an excessive elevation of plasmin-antiplasmin complexes (9,200 ng/ml; <z:mpath ids='MPATH_458'>normal</z:mpath> range: 10-150), an elevated D-dimer, and an increase in thrombin-antithrombin III complexes were found </plain></SENT>
<SENT sid="4" pm="."><plain>The identity of the circulating MC was confirmed by immunophenotyping (CD117/c-kit+, CD123/IL-3R alpha-, CD11b/C3biR-), biochemical analysis (cellular ratio [ng:ng] of tryptase to <z:chebi fb="11" ids="18295">histamine</z:chebi> &gt;1), and electron microscopy </plain></SENT>
<SENT sid="5" pm="."><plain>Bone marrow (bm) examination showed trilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (17% blasts), 30% diffusely scattered MC, and a complex karyotype </plain></SENT>
<SENT sid="6" pm="."><plain>No dense, compact MC infiltrates (<z:hpo ids='HP_0100495'>mastocytosis</z:hpo>) were detectable in bm sections </plain></SENT>
<SENT sid="7" pm="."><plain>Despite hyperfibrinolysis and mediator syndrome (flushing, <z:hpo ids='HP_0002315'>headache</z:hpo>), the patient received remission induction polychemotherapy (DAV) followed by two cycles of consolidation with intermediate dose ARA-C (2 x 1 g/m2/day on days 1, 3, and 5) </plain></SENT>
<SENT sid="8" pm="."><plain>He entered complete remission after the first chemotherapy cycle without evidence of recurring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, in response to chemotherapy, the hyperfibrinolysis and mediator syndrome resolved, and the circulating c-kit+ MC disappeared </plain></SENT>
<SENT sid="10" pm="."><plain>We suggest consideration of polychemotherapy as a therapeutic option in patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> of recent <z:hpo ids='HP_0003674'>onset</z:hpo>, even in the case of MC lineage involvement </plain></SENT>
</text></document>